Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04895696
Other study ID # IM026-024
Secondary ID 2023-504320-25-0
Status Recruiting
Phase Phase 2
First received
Last updated
Start date October 11, 2021
Est. completion date April 22, 2029

Study information

Verified date May 2024
Source Bristol-Myers Squibb
Contact BMS Study Connect Contact Center www.BMSStudyConnect.com
Phone 855-907-3286
Email Clinical.Trials@bms.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythematosus (SLE). The extension period will provide additional long-term safety and efficacy data and enable those participants initially randomized to placebo to receive treatment with Afimetoran.


Recruitment information / eligibility

Status Recruiting
Enrollment 268
Est. completion date April 22, 2029
Est. primary completion date March 29, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Diagnosed = 12 weeks before the screening visit and qualify as having SLE according to the SLE International Collaborating Clinics (SLICC) Classification Criteria at the screening visit - Test positive, as determined by the central laboratory, for at least one of the following lupus related autoantibodies at the time of screening: antinuclear antibody = 1:80, anti-double-stranded deoxyribonucleic acid (dsDNA) antibody, or anti-Smith antibody. - Have a total Hybrid Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score = 6 points and clinical Hybrid SLEDAI score = 4 points with joint involvement and/or rash Exclusion Criteria: - Active severe lupus nephritis (LN) as assessed by the investigator - Active or unstable neuropsychiatric lupus manifestations defined by the Hybrid SLEDAI - Diagnosis of Mixed Connective Tissue Disease for which the predominant diagnosis is not SLE - Antiphospholipid Syndrome Other protocol-defined inclusion/exclusion criteria apply

Study Design


Intervention

Drug:
Afimetoran
Specified dose on specified days
Other:
Placebo
Specified dose on specified days

Locations

Country Name City State
Argentina Fundacion Cidea Buenos Aires Distrito Federal
Argentina Fundación Respirar Buenos Aires
Argentina Local Institution - 0207 Buenos Aires
Argentina APRILLUS Asistencia e Investigacion Clinica Caba Distrito Federal
Argentina Local Institution - 0145 Caba Distrito Federal
Argentina Centro Consultora Integral de Salud SRL Córdoba Cordoba
Argentina CER medical Institute-Rheumatology Quilmes Buenos Aires
Argentina Local Institution - 0195 San Fernando Buenos Aires
Argentina CER San Juan-Rheumatology San Juan
Argentina Centro Medico Privado de Reumatologia San Miguel de Tucumán Tucuman
Australia Local Institution - 0063 Botany New South Wales
Australia Local Institution - 0062 Camberwell Victoria
Australia Local Institution - 0064 Ivanhoe Victoria
Australia Local Institution - 0066 Maroochydore Queensland
Australia Westmead Hospital-Department of Clinical Immunology and Allergy Westmead New South Wales
Australia Local Institution - 0065 Woodville South Australia
Brazil IPC-MT Instituto de Pesquisas Clínicas de Mato Grosso Cuiabá Mato Grosso
Brazil Centro de Estudos em Terapias Inovadoras-Rheumatology Curitiba Parana
Brazil Cmip-Centro Mineiro de Pesquisa Juiz de Fora Minas Gerais
Brazil LMK Serviços Médicos S/S-Reumacenter Porto Alegre RIO Grande DO SUL
Brazil Centro de Pesquisas da Clínica IBIS Salvador Bahia
Brazil Serviços Especializados em Reumatologia Salvador Bahia
Brazil Centro Multidisciplinar de Estudos Clinicos São Bernardo do Campo SAO Paulo
Brazil Hospital de Base de São José do Rio Preto-CIP - Centro Integrado de Pesquisas São José do Rio Preto SAO Paulo
Brazil CEPIC - Centro Paulista de Investigação Clínica São Paulo
Brazil Local Institution - 0013 São Paulo SAO Paulo
Chile Local Institution - 0127 Osorno LOS Lagos
Chile Centro Estudios Reumatologicos Santiago Metropolitana
Chile Estudios Clinicos CTR Santiago Región Metropolitana De Santiago
Chile Investigaciones y Terapias Reumatologicas LTDA. INTERIN LTDA Santiago Metropolitana
Chile Sociedad De Prestaciones En Salud De Los Rios Ltda. Valdivia Los Rios
China Local Institution - 0196 Baoding Hebei
China Local Institution - 0177 Beijing Beijing
China Local Institution - 0180 Beijing Beijing
China The First Hospital of Jilin University Changchun Jilin
China Local Institution - 0194 Changzhi Shanxi
China The 2nd Affiliated Hospital of Dalian Medical University Dalian Liaoning
China Qilu Hospital of Shandong University (Qingdao) Jinan Shandong
China Jining No.1 People's Hospital Jining Shandong
China Local Institution - 0181 Kunming Yunnan
China Jiangsu Province Hospital Nanjing Jiangsu
China Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School Nanjing Jiangsu
China The Seventh Affiliated Hospital, Sun Yat-sen University Shenzhen Guangdong
China The First Affiliated Hospital of Soochow University Suzhou Jiangsu
Colombia Local Institution - 0001 Barranquilla
Colombia Centro de Investigacion en Reumatologia y Especialidades Medicas S.A.S Bogotá
Colombia Centro de Estudios de Reumatología y Dermatología SAS Cali
Colombia Local Institution - 0185 Cali Valle Del Cauca
Colombia Preventive Care Chía
Colombia Salud SURA Industriales Medellín Antioquia
Colombia Healthy Medical Center S.A.S Zipaquira
France Bordeaux University Hospital - Pellegrin-Rhumatologie Bordeaux
France CHRU de Brest Brest Finistère
France Centre Hospitalier Universitaire de Caen Normandie Caen
France Chru De Lille Lille Cedex
France Hôpital Européen Marseille-Service de recherche clinique Marseille
France CHU Bordeaux Haut-Leveque Pessac Aquitaine
France CHU Strasbourg-Hautepierre-Service de Rhumatologie Strasbourg
Germany Charité Research Organisation Berlin
Germany Local Institution - 0086 Essen
Germany Klinikum Der Albrecht-Ludwigs-Universitat Freiburg
Germany Local Institution - 0087 Köln Nordrhein-Westfalen
India Local Institution - 0210 Bengaluru Karnataka
India Local Institution - 0214 Gurugram Haryana
India Local Institution - 0209 Hyderabad Telangana
India Local Institution - 0208 New Delhi Delhi
Ireland Local Institution - 0106 Dublin
Ireland Local Institution - 0107 Galway
Ireland Local Institution - 0119 Manorhamilton Leitrim
Japan Koujunkai Daido Clinic Aichi
Japan Juntendo University Hospital Bunkyo-ku Tokyo
Japan National Hospital Organization Chiba-East Hospital Chiba
Japan Local Institution - 0114 Eiheiji-cho,Yoshida-gun Fukui
Japan Tokyo Metropolitan Tama Medical Center Fuchu Tokyo
Japan Local Institution - 0162 Fukushima
Japan Local Institution - 0113 Itabashiku Tokyo
Japan Kanazawa University Hospital Kanazawa Ishikawa
Japan University of Occupational and Enviromental Health Kitakyushu Fukuoka
Japan Local Institution - 0150 Meguro-ku Tokyo
Japan Hokkaido University Hospital Sapporo Hokkaido
Japan Tohoku University Hospital-Department of Rheumatology Sendai-shi Miyagi
Japan Keio university hospital-Division of Rheumatology, Department of Internal Medicine Shinjuku-ku Tokyo
Japan National Center for Global Health and Medicine Shinjuku-ku Tokyo
Japan Local Institution - 0097 Tokyo
Japan Local Institution - 0116 Tokyo
Mexico Mediadvance Clinical-Rheumatology Chihuahua
Mexico Clinica de Investigacion en Reumatologia y Obesidad S. C. Guadalajara Jalisco
Mexico Hospital Aranda de La Parra-Consultorio Médico de Reumatología Leon Guanajuato
Mexico Unidad de Atención Médica e Investigación en Salud Merida
Mexico Centro Medico Dialinde Mexico City Distrito Federal
Mexico CINTRE - Centro de investigacion y tratamiento reumatologico, S.C. Mexico City Distrito Federal
Mexico Local Institution - 0158 Mexico City Distrito Federal
Mexico Local Institution - 0182 Mexico City Distrito Federal
Mexico Accelerium S de RL de CV Monterrey Nuevo LEON
Mexico Investigacion Biomedica para el Desarrollo de Fármacos S.A. de C.V. Zapopan Jalisco
Poland Local Institution - 0051 Bydgoszcz
Poland Local Institution - 0161 Lomza Podlaskie
Poland Medyczne Centrum Hetmanska Poznan
Poland Local Institution - 0142 Rzeszów
Poland Local Institution - 0050 Sosnowiec
Poland Centrum Medyczne Reuma Park Warszawa Mazowieckie
Poland MICS Centrum Medyczne Warszawa Warszawa
Poland Uniwersytecki Szpital Kliniczny-Klinika Reumatologii i Chorób Wewnetrznych Wroclaw
Puerto Rico GCM Medical Group, PSC - Hato Rey Site-Hato Rey San Juan
Puerto Rico Mindful Medical Research San Juan
Romania Hightech Medical Services SRL-Centrul pentru Studiul Metabolismului Bucharest
Romania Spital Clinic Sf. Maria Bucharest
Romania Centrul de Kinetoterapie si Masaj Banat SRL Giroc
Romania SC MEDAUDIO-OPTICA SRL-Rheumatology Râmnicu Vâlcea
Spain CHUAC-Complejo Hospitalario Universitario A Coruña-Reumatologia A Coruña
Spain Hospital Universitari Vall d'Hebron-Rheumatology Barcelona
Spain HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON-Reumatología Madrid
Spain Local Institution - 0206 Santander Cantabria
Spain Hospital Universitario Virgen de Valme-RHEUMATOLOGY Sevilla
Taiwan Chang Gung Memorial Hospital at Kaohsiung-Rheumatology Kaohsiung Niao Sung Dist
Taiwan China Medical University Hospital Taichung
Taiwan Taichung Veterans General Hospital Taichung
Taiwan National Taiwan University Hospital-Immunology Taipei
Taiwan Taipei Veterans General Hospital Taipei
United Kingdom Local Institution - 0110 Bradford
United Kingdom Local Institution - 0111 Cambridge Cambridgeshire
United Kingdom Local Institution - 0120 Edinburgh
United Kingdom Local Institution - 0125 Manchester
United States Allen Arthritis Allen Texas
United States Arthritis and Rheumatology Research Institute Allen Texas
United States Amarillo Center for Clinical Research-Research Amarillo Texas
United States Piedmont West Atlanta Georgia
United States Ochsner Medical Complex - The Grove Baton Rouge Louisiana
United States University of Alabama at Birmingham Birmingham Alabama
United States Bay Area Arthritis and Osteoporosis Brandon Florida
United States Jacobi Medical Center-Research Bronx New York
United States DJL Clinical Research, PLLC Charlotte North Carolina
United States Local Institution - 0203 Charlotte North Carolina
United States Clinical Research of West Florida, Inc. (Clearwater) Clearwater Florida
United States The Ohio State University Wexner Medical Center (OSUWMC) - CarePoint East-Rheumatology and Immunolog Columbus Ohio
United States Private Practice - Dr. Jefrey Lieberman Decatur Georgia
United States Colorado Arthritis Associates Denver Colorado
United States Saint Paul Rheumatology Eagan Minnesota
United States UConn Health Farmington Connecticut
United States St Joseph Heritage Healthcare-Rheumatology Fullerton California
United States University Of Florida Gainesville Florida
United States Western KY Rheumatology Hopkinsville Kentucky
United States Christine Thai, MD Huntington Beach California
United States Vida Clinical Research Kissimmee Florida
United States UCSD - Altman Clinical and Translational Research Institute (ACTRI) La Jolla California
United States Advanced Medical Research - La Palma La Palma California
United States Local Institution - 0091 Las Vegas Nevada
United States North Georgia Rheumatology Lawrenceville Georgia
United States Local Institution - 0202 Los Angeles California
United States The Feinstein Institute for Medical Research Manhasset New York
United States Shelby Research LLC Memphis Tennessee
United States Southwest Rheumatology Research Mesquite Texas
United States Paramount Medical Research and Consulting, Llc Middleburg Heights Ohio
United States Oklahoma Medical Research Foundation Oklahoma City Oklahoma
United States Oklahoma Medical Research Foundation-Multiple Sclerosis Center of Excellence Oklahoma City Oklahoma
United States Greater Chicago Specialty Physicians - Orland Park Orland Park Illinois
United States Omega Research MetroWest Orlando Florida
United States Millennium Research Ormond Beach Florida
United States IRIS Research and Development, LLC Plantation Florida
United States Local Institution - 0221 Rochester Hills Michigan
United States Arthritis Consultants, Inc. Saint Louis Missouri
United States Washington University/ Barnes Jewish Hospital Saint Louis Missouri
United States Sun Research Institute San Antonio Texas
United States Rheumatology Center of San Diego San Diego California
United States Clin-Med Research & Development - 6141 Sunset Drive South Miami Florida
United States West Broward Rheumatology Associates Tamarac Florida
United States Private Practice - Dr. Nazanin Firooz West Hills California
United States Local Institution - 0134 Wheaton Maryland
United States Center for Rheumatology Research Woodland Hills California

Sponsors (1)

Lead Sponsor Collaborator
Bristol-Myers Squibb

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Brazil,  Chile,  China,  Colombia,  France,  Germany,  India,  Ireland,  Japan,  Mexico,  Poland,  Puerto Rico,  Romania,  Spain,  Taiwan,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of participants that achieve an SLE (Systemic Lupus Erythematosus) Responder Index (4) (SRI(4)) response at Week 48 Up to 48 Weeks
Secondary Proportion of participants that achieve a British Isles Lupus Assessment Group (BILAG)-based Combine Lupus Assessment (BICLA) response at Week 24 and Week 48 Up to 48 Weeks
Secondary Proportion of participants who achieve an SRI(4) response at Week 24 Up to 24 Weeks
Secondary Proportion of participants who achieve a Lupus Low Disease Activity State (LLDAS) response at Week 24 and Week 48 Up to 48 Weeks
Secondary Proportion of participants with a Cutaneous Lupus Erythematosus Disease Area and Severity Index; Activity (CLASI-A) score = 10 at baseline who achieve a decrease of = 50% from baseline CLASI-A score (CLASI-50) response at Week 24 and Week 48 Up to 48 Weeks
Secondary Proportion of participants with 6 or more swollen joints and 6 or more tender joints at baseline who achieve a = 50% reduction from baseline in both swollen and tender joints at Week 24 and Week 48 Up to 48 Weeks
Secondary Mean change from baseline in swollen joint count using the 28-joint count at Week 24 and Week 48 in participants with = 2 swollen joints at baseline Up to 48 Weeks
Secondary Mean change from baseline in tender joint count at Week 24 and Week 48 using the 28- joint count in participants with = 2 tender joints at baseline Up to 48 Weeks
Secondary Change from baseline in PGA score of disease activity at Week 24 and Week 48 PGA = Physician Global Assessment of disease activity (score of "0" indicating no disease activity and higher scores indicating higher disease activity) Up to 48 Weeks
Secondary Proportion of participants who achieve CS reduction or maintenance to = 7.5 mg per day at Week 48 Up to 48 Weeks
Secondary Change in participant reported disease activity from baseline to Week 24 and Week 48 according to the 36-item Short Form Health Questionnaire (SF-36) The SF-36 was designed as an indicator of health status in population surveys, and health policy evaluations, and for use as an outcome measure in clinical practice and research. Scores for each domain range from 0 to 100, with high scores indicating a better health status. Up to 48 Weeks
Secondary Number of participants with Adverse Events (AEs) Up to 100 Weeks
Secondary Number of participants with Serious Adverse Events (SAEs) Up to 100 Weeks
Secondary Number of participants with clinical laboratory abnormalities Up to 100 Weeks
Secondary Number of participants with physical examination abnormalities Up to 100 Weeks
Secondary Number of participants with vital sign abnormalities Up to 100 Weeks
Secondary Number of participants with electrocardiogram (ECG) abnormalities Up to 52 Weeks
See also
  Status Clinical Trial Phase
Terminated NCT03843125 - A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE) Phase 3
Recruiting NCT05698173 - Systemic Lupus Erythematosus and Accelerated Aging N/A
Active, not recruiting NCT01649765 - Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy Phase 2
Recruiting NCT05704153 - Modelling and Control of Non-invasive Vagus Nerve Stimulation for Autoimmune Diseases (1A) N/A
Completed NCT05048238 - Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus Phase 1
Recruiting NCT06056778 - The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)
Completed NCT04358302 - Individual Patient Exposure and Response in Pediatric Lupus N/A
Completed NCT03802578 - The Impact of Exercise on Hand Function, Daily Activities Performance and Quality of Life of SLE' Patients N/A
Completed NCT02554019 - Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus Phase 2
Recruiting NCT04835883 - Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients Phase 2
Terminated NCT02665364 - Phase IIb Study of IFN-K in Systemic Lupus Erythematosus Phase 2
Completed NCT00278538 - Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus Phase 2
Completed NCT00069342 - Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases
Completed NCT03252587 - An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus Phase 2
Terminated NCT02066311 - Nelfinavir in Systemic Lupus Erythematosus Phase 2
Recruiting NCT01892748 - Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus. N/A
Terminated NCT01689025 - An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE) Phase 1
Completed NCT01475149 - Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE) N/A
Unknown status NCT01712529 - Physical Exercise, Endothelial Function and Progenitor Endothelial Cells in Systemic Lupus Erythematosus Patients N/A
Completed NCT00962832 - A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus Phase 2